Preview Mode Links will not work in preview mode

 

Welcome to the Empowered Patient Podcast with Karen Jagoda.  This show is a window into the latest innovations in digital health and the changing dynamic between doctors and patients.

Topics on the show include

  • the emergence of precision medicine and breakthroughs in genomics
  • advances in biopharmaceuticals
  • age-related diseases and aging in place
  • using big data from wearables and sensors
  • transparency in the medical marketplace
  • challenges for connected health entrepreneurs

The audience includes researchers, medical professionals, patient advocates, entrepreneurs, patients, caregivers, solution providers, students, journalists, and investors.

Dec 20, 2021

Kathy Lee-Sepsick is the President, CEO, and Founder of Femasys, and not looking at minor levels of improvement in women's healthcare, but products and technologies that change the standard of care.  With a focus on reproductive health, they are looking at infertility as well as a permanent birth control option for women.

Kathy explains, "So one of our major products is called FemVue. And what we did here is another example of what we're trying to do in these other product categories. We have developed a way to move an essential test for infertility diagnosis from radiology back to her GYN, utilizing ultrasound. So FemVue offers a saline and air contrast, or we call it bubbles, where those bubbles enable the evaluation and viewing of her fallopian tubes, which is suspect when a physician is evaluating all potential infertility factors."

"And at the same time, we are also advancing through clinical trial work, our FemBloc solution, which is our permanent birth control option for women. And both of those are delivered in an office environment. OBGYNs are performing the FemBloc procedure, and that's performed domestically as well in an active clinical trial."

@FemasysInc #ReproductiveHealth #WomensHealth #BirthControl #Infertility #FemBloc #FemVue

Femasys.com

Download the transcript here

Femasys